Your browser doesn't support javascript.
Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19.
Fouladseresht, Hamed; Doroudchi, Mehrnoosh; Rokhtabnak, Najmeh; Abdolrahimzadehfard, Hossein; Roudgari, Amir; Sabetian, Golnar; Paydar, Shahram.
  • Fouladseresht H; Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: fouladsereshtimmunology@gmail.com.
  • Doroudchi M; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Rokhtabnak N; Department of Biology, Faculty of Science, Shahid Bahonar University of Kerman, Kerman, Iran.
  • Abdolrahimzadehfard H; Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Roudgari A; Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Sabetian G; Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Paydar S; Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Cytokine Growth Factor Rev ; 58: 32-48, 2021 04.
Article in English | MEDLINE | ID: covidwho-1163617
ABSTRACT
The coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), appears with a wide spectrum of mild-to-critical clinical complications. Many clinical and experimental findings suggest the role of inflammatory mechanisms in the immunopathology of COVID-19. Hence, cellular and molecular mediators of the immune system can be potential targets for predicting, monitoring, and treating the progressive complications of COVID-19. In this review, we assess the latest cellular and molecular data on the immunopathology of COVID-19 according to the pathological evidence (e.g., mucus and surfactants), dysregulations of pro- and anti-inflammatory mediators (e.g., cytokines and chemokines), and impairments of innate and acquired immune system functions (e.g., mononuclear cells, neutrophils and antibodies). Furthermore, we determine the significance of immune biomarkers for predicting, monitoring, and treating the progressive complications of COVID-19. We also discuss the clinical importance of recent immune biomarkers in COVID-19, and at the end of each section, recent clinical trials in immune biomarkers for COVID-19 are mentioned.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Biomarkers / COVID-19 / Immunity, Innate / Monitoring, Physiologic Type of study: Diagnostic study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Cytokine Growth Factor Rev Journal subject: Allergy and Immunology / Biochemistry Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Biomarkers / COVID-19 / Immunity, Innate / Monitoring, Physiologic Type of study: Diagnostic study / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Cytokine Growth Factor Rev Journal subject: Allergy and Immunology / Biochemistry Year: 2021 Document Type: Article